Table. COVID-19 vaccine primary and further dose recommendations for people with medical conditions that increase their risk of severe illness
“Recommended”: benefits of vaccination outweigh the risks for the defined population.
“Consider”: shared decision making between an individual and their healthcare provider.
| Age group | Level of immunocompromise | Primary course recommendations | Further (booster) dose recommendations |
|---|---|---|---|
| Age 6 months to <5 years | Medical risk condition without severe immunocompromise | Consider 2 doses, at least 8 weeks apart | Not recommended |
| Severe immunocompromise | Consider 2-3 doses, at least 8 weeks apart | Not recommended | |
| Age 5 years to <18 years | Medical risk condition without severe immunocompromise | Consider 1 primary dose | Not recommended |
| Severe immunocompromise | Consider 1-2 primary doses, at least 8 weeks apart | Consider 1 further dose every 12 months | |
| Age 18–64 years | Medical risk condition without severe immunocompromise | Recommended 1 primary dose | Consider 1 further dose every 12 months |
| Severe immunocompromise | Recommended 2 primary doses and consider a 3rd, at least 8 weeks apart | Recommended 1 further dose every 12 months but can be considered every 6 months | |
| Age 65–74 years | Medical risk condition without severe immunocompromise | Recommended 1 primary dose | Recommended 1 further dose every 12 months but can be considered every 6 months |
| Severe immunocompromise | Recommended 2 primary doses and consider a 3rd, at least 8 weeks apart | Recommended 1 further dose every 12 months, but can be considered every 6 months | |
| Age ≥75 years | Medical risk condition without severe immunocompromise | Recommended 1 primary dose | Recommended 1 further dose every 6 months |
| Severe immunocompromise | Recommended 2 primary doses and consider a 3rd, at least 8 weeks apart | Recommended 1 further dose every 6 months |
Page history
Last updated
Last reviewed
Related diseases